Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health Inc (NASDAQ: JAGX) delivers innovative plant-based therapeutics for gastrointestinal health across human and animal populations. This news hub provides investors and healthcare professionals with essential updates about the company’s clinical developments, regulatory milestones, and sustainable pharmaceutical innovations.
Access official press releases and verified news covering key areas including FDA approvals for Mytesi® (crofelemer), veterinary health product developments like Canalevia™, clinical trial progress, and strategic partnerships. Our curated collection ensures timely updates on JAGX’s advancements in non-opioid anti-secretory treatments and ecological sourcing practices.
Discover updates across multiple categories: new product launches, research collaborations, financial disclosures, intellectual property developments, and sustainability initiatives. Each update is vetted for accuracy, providing reliable insights into Jaguar Health’s progress in addressing chronic diarrhea conditions and neglected gastrointestinal disorders.
Bookmark this page for streamlined access to Jaguar Health’s latest developments. Check back regularly for updates on their unique approach to combining traditional botanical knowledge with modern pharmaceutical science through subsidiaries like Napo Pharmaceuticals.
Napo EU, a target of Dragon SPAC, aims to develop crofelemer to treat short bowel syndrome (SBS), having received orphan-drug designation from the US FDA. The merger of Napo EU and Dragon SPAC is anticipated to finalize within 80 days, with potential license and milestone fees up to $12.5 million. Recent financing closed with €8.83 million (approx. $10.8 million) from Jaguar Health, Inc. (NASDAQ:JAGX). The global SBS market is projected to grow from $568 million in 2019 to $4.6 billion by 2027.
Jaguar Health (NASDAQ:JAGX) announced the completion of the Phase 2 HALT-D study, investigating Mytesi® (crofelemer) for diarrhea relief in HER2 positive breast cancer patients undergoing chemotherapy. Sponsored by Georgetown University and funded by Genentech, results have been submitted for presentation at the San Antonio Breast Cancer Symposium in December 2021. The study aims to address common chemotherapy-related diarrhea, which can hinder treatment adherence and patient outcomes. Jaguar looks forward to potential publication of these results, separate from the ongoing Phase 3 trial of crofelemer.
Jaguar Health, Inc. (NASDAQ:JAGX) has adjourned its Annual Meeting of Stockholders for the third time due to insufficient quorum. Over 74% of votes cast favor Proposals 2, 3, 4, and 6. The meeting will reconvene on August 6, 2021, at 8:30 AM PST to encourage more participation. As of April 12, 2021, stockholders are reminded to vote if they haven't done so. The company emphasizes that approximately 2.9% of eligible stock must vote to reach quorum. The proposals remain unchanged, and voting options are provided for stockholders.
Jaguar Health (NASDAQ:JAGX) will join the Russell Microcap Index effective June 28, 2021, enhancing its visibility and potentially broadening its institutional shareholder base. The inclusion in this index reflects Jaguar's market capitalization and growth attributes, which can attract investment managers looking for benchmarked stocks. This milestone aligns with the company's ongoing efforts to expand access to crofelemer, its plant-based product approved for treating noninfectious diarrhea in adults with HIV/AIDS.
Jaguar Health, Inc. (Nasdaq:JAGX) has adjourned its Annual Meeting of Stockholders originally scheduled for May 13, 2021, due to lack of quorum. The meeting will reconvene on July 9, 2021. Preliminary votes indicate over 76% support for key proposals, particularly Proposal 3, which seeks to increase the authorized shares of Common Stock from 150 million to 290 million. This increase aims to provide flexibility for future business needs and potential capital raises. The record date for eligible stockholders remains April 12, 2021.
Jaguar Health, Inc. (NASDAQ:JAGX) announced on June 4, 2021, the grant of stock options and restricted stock units (RSUs) to a new employee as inducement awards. Effective May 27, 2021, the company granted nonstatutory stock options for 225,000 shares with an exercise price of $1.68 per share, vesting over three years. Additionally, 112,500 RSUs were granted, vesting similarly over three years. These grants were approved by the Compensation Committee and are contingent on the employee's continued service.
Jaguar Health (NASDAQ:JAGX) announced a webcast interview with CEO Lisa Conte and Dragon SPAC founding sponsor Josh Mailman, scheduled for June 3, 2021, at 8:30 AM ET. The discussion will center on plans for Napo EU S.p.A., the company's Italian subsidiary, to seek conditional marketing authorization for crofelemer from the European Medicines Agency for treating short bowel syndrome (SBS), which leads to severe nutrient absorption issues. Jaguar aims to expand crofelemer access in Europe, capitalizing on its unique plant-based drug profile.
Jaguar Health and Dragon SPAC announced a private financing of approximately US$10.8 million to support the merger with Napo EU S.p.A. The funds will help pursue conditional marketing authorization for crofelemer, targeting short bowel syndrome, a market projected to reach US$4.6 billion by 2027. The deal involves Dragon SPAC issuing units, each including one ordinary share and a warrant. The financing is expected to close by Q2 2021, with the merger likely finalized within 30 days. This strategic shift aims to meet an unmet medical need in gastrointestinal health.
Jaguar Health and Dragon SPAC announced initial funding of $10.8 million for the Dragon SPAC private financing, aimed at facilitating a business combination with Napo EU, its Italian subsidiary. Napo EU plans to pursue conditional marketing authorization in the EU for crofelemer, targeting short bowel syndrome (SBS), a rare gastrointestinal condition. This orphan drug designation offers incentives like reduced fees and market exclusivity. The SBS market is projected to grow from $568 million in 2019 to $4.6 billion by 2027, with a CAGR of 26%.
Napo Pharmaceuticals, a subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), appointed Dr. Darlene Horton as Chief Medical Officer. Dr. Horton, a biopharmaceutical veteran, will enhance the company's phase 3 clinical trial for crofelemer, aimed at preventing cancer therapy-related diarrhea. Her extensive experience spans multiple therapeutic areas, having held senior roles at several biotech firms. The company is also pursuing conditional marketing authorization from the European Medicines Agency for crofelemer. This appointment is expected to drive further development of innovative gastrointestinal treatments.
